Ambrisentan is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical deterioration. PAH is characterized by increased pressure in the pulmonary arteries, which can lead to heart failure. Ambrisentan helps reduce pulmonary vascular resistance and improve cardiac output, thereby enhancing the patient's exercise tolerance and overall quality of life.

Ambrisentan tablets should be taken orally once daily. The typical starting dose is 5 mg once daily. If well tolerated, the dose may be increased to 10 mg once daily, depending on the patient's clinical response. Dosage adjustments may be required in cases of hepatic impairment or other health conditions. The drug should be taken with or without food, and it is essential to follow the dosing schedule without missing doses. Regular monitoring of liver function is advised due to the potential for hepatotoxicity.